Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator

Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion

(2018) Krister Bamberg et al.   PLoS One

The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY

(2017) Simon D Harding et al.   NUCLEIC ACIDS RESEARCH

Pharmacokinetics of oral fludrocortisone in septic shock

(2016) Andrea Polito et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies

(2016) Silvia Lentini et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

Response to: Hyperkalaemia in heart failure: binding the patient to improved treatment?

(2015) Bertram Pitt et al.   EUROPEAN JOURNAL OF HEART FAILURE

Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy

(2015) George L. Bakris et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Validation of the IntelliCap® system as a tool to evaluate extended release profiles in human GI tract using metoprolol as model drug

(2015) Erik Söderlind et al.   JOURNAL OF CONTROLLED RELEASE

Evidence for a gastrointestinal–renal kaliuretic signaling axis in humans

(2015) Richard A. Preston et al.   KIDNEY INTERNATIONAL

A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010

(2015) Katherine T. Mills et al.   KIDNEY INTERNATIONAL

Selective glucocorticoid receptor modulation: New directions with non-steroidal scaffolds

(2015) Nora Sundahl et al.   PHARMACOLOGY & THERAPEUTICS

Prediction and Management of Hyperkalemia Across the Spectrum of Chronic Kidney Disease

(2014) Ivana Lazich et al.   SEMINARS IN NEPHROLOGY

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial

(2013) Bertram Pitt et al.   EUROPEAN HEART JOURNAL

Spironolactone Reduces Cardiovascular and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients

(2013) Yoshihiro Matsumoto et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention

(2013) Ron T Gansevoort et al.   LANCET

Evolving importance of kidney disease: from subspecialty to global health burden

(2013) Kai-Uwe Eckardt et al.   LANCET

PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy

(2013) Stephen Orena et al.   Frontiers in Pharmacology

Human plasma quantification of fludrocortisone using liquid chromatography coupled with atmospheric pressure chemical ionization mass spectrometry after low-dosage administration

(2012) Mégane Ribot et al.   CLINICA CHIMICA ACTA

The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism

(2011) Rena J Eudy et al.   Journal of Translational Medicine

Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease

(2011) Jean-Philippe Bertocchio et al.   KIDNEY INTERNATIONAL

Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts

(2011) Marije van der Velde et al.   KIDNEY INTERNATIONAL

SERMs: Progress and future perspectives

(2010) James H. Pickar et al.   MATURITAS

Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

(2010) Faiez Zannad et al.   NEW ENGLAND JOURNAL OF MEDICINE